Why the study?
Does caspase inhibition prevent adverse cardiac remodeling in a transgenic mouse model of TNF overexpression?
Population
Transgenic myosin heavy chain secreted TNF mice with cardiac restricted overexpression of tumor necrosis…
Comparison
Broad-based caspase inhibitor… vs Untreated/control MHCsTNF mice
Design
Preclinical
Follow-up
4 to 12 weeks
Authors
Loading...
Caspase inhibition shows preclinical promise in TNF-driven cardiomyopathy; leaves open translation to human heart failure.
Does caspase inhibition prevent adverse cardiac remodeling in a transgenic mouse model of TNF overexpression?
Progressive cardiac myocyte apoptosis contributes to adverse cardiac remodeling, and its inhibition attenuates LV wall thinning in a mouse model of TNF overexpression.
Engel et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: